For best experience please turn on javascript and use a modern browser!
You are using a browser that is no longer supported by Microsoft. Please upgrade your browser. The site may not present itself correctly if you continue browsing.

Dr. C. (Colette) Moses

Faculty of Science
Swammerdam Institute for Life Sciences

Visiting address
  • Science Park 904
Postal address
  • Postbus 94246
    1090 GE Amsterdam
Contact details
  • Profile

    I have always been fascinated by the incredible complexity of the human brain, which defines our identity and gives us uniquely human capabilities — and I want to find out how we can avoid the devastating consequences when something in our brain goes wrong.

    My research focuses on genes involved in human brain development that contribute to rare neurodevelopmental diseases, as well as more common disorders like autism and intellectual disability. I am particularly interested in genes with human-specific features, found in highly duplicated regions of the genome. These genes were generated recently in hominid evolution, and may be responsible for the large size and complexity of the human neocortex, which gives us our cognitive capabilities. The duplications in human-specific regions make them highly unstable and prone to recombination, and deletions or duplications in these regions often result in neurodevelopmental disorders.

    I aim to discover the function of particular genes in human brain development and disease by conducting CRISPR gene editing in human pluripotent stem cells, which I use to generate forebrain-type cortical organoids. I hope to better understand the function of human-specific genes, and the contribution of different genes to neurodevelopmental disorders. My work is part of a collaboration between Psychiatrists, Clinical Neuropsychologists, Geneticists and Neurobiologists at Radboud University, Leiden University and the University of Amsterdam. We hope that our combined efforts will enable us to generate new perspectives and insights into the mechanisms underlying neurodevelopmental disease, and to feed these insights back to directly benefit patients.

  • Publications

    2023

    • Waryah, C., Cursons, J., Foroutan, M., Pflueger, C., Wang, E., Molania, R., Woodward, E., Sorolla, A., Wallis, C., Moses, C., Glas, I., Magalhães, L., Thompson, E. W., Fearnley, L. G., Chaffer, C. L., Davis, M., Papenfuss, A. T., Redfern, A., Lister, R., ... Blancafort, P. (2023). Synthetic Epigenetic Reprogramming of Mesenchymal to Epithelial States Using the CRISPR/dCas9 Platform in Triple Negative Breast Cancer. Advanced Science, 10(22), Article 2301802. https://doi.org/10.1002/advs.202301802

    2022

    • van Bree, E. J., Guimarães, R. L. F. P., Lundberg, M., Blujdea, E. R., Rosenkrantz, J. L., White, F. T. G., Poppinga, J., Ferrer-Raventós, P., Schneider, A-F. E., Clayton, I., Haussler, D., Reinders, M. J. T., Holstege, H., Ewing, A. D., Moses, C., & Jacobs, F. M. J. (2022). A hidden layer of structural variation in transposable elements reveals potential genetic modifiers in human disease-risk loci. Genome Research, 32(4), 656-670. https://doi.org/10.1101/gr.275515.121

    2020

    • Moses, C., Hodgetts, S. I., Nugent, F., Ben-Ary, G., Park, K. K., Blancafort, P., & Harvey, A. R. (2020). Transcriptional repression of PTEN in neural cells using CRISPR/dCas9 epigenetic editing. Scientific Reports, 10(1), 11393.

    2019

    • Kretzmann, J. A., Evans, C., Moses, C., Sorolla, A., Kretzmann, A., Wang, E., Ho, D., Hackett, M., Dessauvagie, B., Smith, N. M., Redfern, A., Waryah, C., Norret, M., Iyer, S., & Blancafort, P. (2019). Tumour suppression by targeted intravenous non-viral CRISPRa using dendritic polymers. Chemical Science, 10(33), 7718-7727.
    • Moses, C., & Kaur, P. (2019). Applications of CRISPR systems in respiratory health – entering a new “red pen” era in genome editing. Respirology, 24(7), 628-637.
    • Moses, C., Nugent, F., Waryah, C. B., Garcia-Bloj, B., Harvey, A. R., & Blancafort, P. (2019). Activating PTEN tumor suppressor expression with the CRISPR/dCas9 system. Molecular Therapy. Nucleic Acids, 14, 287-300.

    2018

    • Moses, C., Garcia-Bloj, B., Harvey, A. R., & Blancafort, P. (2018). Hallmarks of cancer: The CRISPR generation. European Journal of Cancer, 93, 10-18.
    • Waryah, C. B., Moses, C., Arooj, M., & Blancafort, P. (2018). Zinc Fingers, TALEs and CRISPR systems: A comparison of tools for epigenome editing. In A. Jeltsch, & M. G. Rots (Eds.), Epigenome Editing: Methods and Protocols (pp. 19-63). (Methods in Molecular Biology; Vol. 1767). Humana Press. https://doi.org/10.1007/978-1-4939-7774-1_2

    2016

    • Garcia-Bloj, B., Moses, C., Sgro, A., Plani-Lam, J., Arooj, M., Duffy, C., Thiruvengadam, S., Sorolla, A., Rashwan, R., Mancera, R. L., Leisewitz, A., Swift-Scanlan, T., Corvalan, A. H., & Blancafort, P. (2016). Waking up dormant tumor suppressor genes with zinc fingers, TALEs and the CRISPR/dCas9 system. Oncotarget, 7(37), 60535-60554.
    • You, S. W., Hellstrom, M., Pollett, M. A., LeVaillant, C., Moses, C., Rigby, P. J., Penrose, M., Rodger, J., & Harvey, A. R. (2016). Large-scale reconstitution of a retina-to-brain pathway in adult rats using gene therapy and bridging grafts: An anatomical and behavioral analysis. Experimental Neurology, 279, 197-211.

    2015

    • Garcia-Bloj, B., Moses, C., & Blancafort, P. (2015). The CRISPR road: from bench to bedside on an RNA-guided path. Annals of translational Medicine, 3(13), 174. https://doi.org/10.3978/j.issn.2305-5839.2015.07.20
    • Moses, C., Wheeler, L. P., LeVaillant, C. J., Kramer, A., Ryan, M., Cozens, G. S., Sharma, A., Pollett, M. A., Rodger, J., & Harvey, A. R. (2015). The acquisition of target dependence by developing rat retinal ganglion cells. eNeuro, 2(3), Article 0044. https://doi.org/10.1523/ENEURO.0044-14.2015

    Prize / grant

    • Moses, C. (2020). EMBO Postdoctoral Fellowship.
    This list of publications is extracted from the UvA-Current Research Information System. Questions? Ask the library or the Pure staff of your faculty / institute. Log in to Pure to edit your publications. Log in to Personal Page Publication Selection tool to manage the visibility of your publications on this list.
  • Ancillary activities
    No ancillary activities